GO:0033314 mitotic DNA replication checkpoint signaling: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0033314 (mitotic DNA replication checkpoint signaling) is the signal transduction process that couples DNA replication status to mitotic entry, preventing cells from dividing before their genomes are fully duplicated.
• The checkpoint operates through a kinase relay (ATR, CHEK1, WEE1) that inhibits CDK1-Cyclin B, creating a 'brake' on mitotic entry until replication is complete.
• Loss of this checkpoint causes mitotic catastrophe, genome instability, and is a hallmark of cancer and congenital microcephaly.
• Whole-genome doubling and DNA damage response alterations create unique vulnerabilities that can be exploited therapeutically by targeting checkpoint kinases.
• Key genes include ATR, ATM, CHEK1, CHEK2, WEE1, CDC25, CDK1, CCNB1, and the replication machinery (MCM, CDC45, TOPBP1).
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential for dissecting checkpoint gene function and validating drug targets.
Description
The mitotic DNA replication checkpoint signaling pathway (GO:0033314) is a conserved surveillance mechanism that ensures genomic integrity by delaying mitotic entry when DNA replication is incomplete or stalled. This biological process integrates signals from the replication machinery with the cell cycle engine, ultimately inhibiting the CDK1-Cyclin B complex that drives mitosis. The checkpoint is critical for preventing mitotic catastrophe, a form of cell death that occurs when cells attempt to divide with damaged or incompletely replicated DNA. Dysregulation of this checkpoint is implicated in a wide range of human pathologies, including cancer, where checkpoint loss promotes genome instability and tumor progression, and congenital microcephaly, where defective checkpoint signaling leads to neurodevelopmental defects. Recent studies have shown that whole-genome doubling, a common event in tumors, confers unique genetic vulnerabilities that can be targeted by disrupting checkpoint pathways. Understanding the molecular players and regulatory logic of GO:0033314 is therefore essential for both basic cell biology and therapeutic development. This article provides a comprehensive overview of the mitotic DNA replication checkpoint signaling pathway, covering its definition, core mechanisms, key genes, disease associations, and state-of-the-art research methods including CRISPR-based models. All facts are drawn from authoritative QuickGO data and verified PubMed literature.
mitotic DNA replication checkpoint signaling At A Glance
| GO ID | GO:0033314 |
|---|---|
| GO term | mitotic DNA replication checkpoint signaling |
| Ontology | biological_process |
| Synonym | S-M checkpoint; S-phase checkpoint; mitotic DNA replication checkpoint; S-M DNA replication checkpoint |
| Major function | Signal transduction that delays mitotic entry when DNA replication is incomplete or stalled |
| Key kinases | ATR, ATM, CHEK1, CHEK2, WEE1 |
| Key targets | CDK1-Cyclin B complex, CDC25 phosphatases |
| Associated diseases | Cancer, congenital microcephaly, genome instability syndromes |
What Is GO:0033314?
GO:0033314 (mitotic DNA replication checkpoint signaling) is defined as a signal transduction process that contributes to a mitotic DNA replication checkpoint. It encompasses the signaling events that detect incomplete or stalled DNA replication during S phase and transmit this information to the cell cycle machinery, ultimately preventing entry into mitosis until replication is complete. This process is synonymous with the S-M checkpoint, S-phase checkpoint, and mitotic DNA replication checkpoint.
Why Is mitotic DNA replication checkpoint signaling Important in Cell Biology?
The mitotic DNA replication checkpoint is a fundamental safeguard for genome stability. By preventing cells from entering mitosis with incompletely replicated or damaged DNA, it avoids the catastrophic consequences of unequal chromosome segregation and DNA breakage. This checkpoint is particularly important in cancer biology, where its dysfunction contributes to the genome instability that drives tumor evolution and creates therapeutic vulnerabilities. Moreover, the checkpoint is essential for normal development, as evidenced by congenital microcephaly syndromes caused by mutations in checkpoint genes.
• Prevents mitotic catastrophe by blocking entry into mitosis when replication is incomplete.
• Maintains genome stability by coordinating DNA replication with cell division.
• Dysregulated in many cancers, contributing to genome instability and tumor progression.
• Provides therapeutic targets: checkpoint kinase inhibitors (e.g., ATR, CHEK1, WEE1 inhibitors) are in clinical trials.
• Whole-genome doubling in tumors creates unique dependencies on checkpoint pathways.
• Mutations in checkpoint genes cause congenital microcephaly and neurodevelopmental disorders.
• Essential for understanding the cell cycle brake model of mitotic entry control.
• Plays a role in the DNA damage response network, integrating with ATM/ATR signaling.
• Targeted by agricultural chemicals and environmental toxicants, with implications for human health.
• Serves as a model for studying signal transduction and cell cycle checkpoints.
What Happens During mitotic DNA replication checkpoint signaling?
Replication stress detection
In simple terms: The cell senses that DNA copying is not going smoothly.
The checkpoint is activated when the replication machinery encounters obstacles such as DNA damage, nucleotide depletion, or replication fork stalling. The ATR kinase, in complex with ATRIP, is recruited to single-stranded DNA regions coated with RPA, a common intermediate at stalled forks. This recruitment triggers a signaling cascade that ultimately inhibits mitotic entry.
Signal amplification by CHEK1
In simple terms: A molecular alarm is amplified to ensure the message is heard.
ATR phosphorylates and activates the effector kinase CHEK1 (Chk1). Activated CHEK1 amplifies the checkpoint signal and phosphorylates downstream targets including the CDC25 phosphatases (CDC25A, CDC25B, CDC25C). Phosphorylation of CDC25 leads to its inhibition or degradation, preventing the removal of inhibitory phosphates on CDK1.
Inhibition of CDK1-Cyclin B
In simple terms: The engine that drives cell division is kept switched off.
The ultimate target of the checkpoint is the CDK1-Cyclin B complex, whose activation is required for mitotic entry. CHEK1-mediated inhibition of CDC25 phosphatases, together with activation of the WEE1 kinase (which adds inhibitory phosphates to CDK1), maintains CDK1 in an inactive state. This creates a 'brake' on mitosis until replication is complete.
Recovery and mitotic entry
In simple terms: Once DNA copying is finished, the brake is released and the cell divides.
When replication is successfully completed, the checkpoint signal is extinguished. This involves the inactivation of ATR and CHEK1, and the reactivation of CDC25 phosphatases, which remove inhibitory phosphates from CDK1. The active CDK1-Cyclin B complex then triggers the events of mitosis, including nuclear envelope breakdown and chromosome condensation.
Integration with DNA damage response
In simple terms: The replication checkpoint talks to the DNA repair machinery.
The mitotic DNA replication checkpoint is closely integrated with the broader DNA damage response (DDR). ATM and ATR kinases coordinate responses to different types of DNA lesions, and cross-talk between these pathways ensures that cells do not divide with damaged DNA. This integration is critical for maintaining genome integrity and is often disrupted in cancer cells.
Key Genes Involved in GO:0033314 mitotic DNA replication checkpoint signaling
The following genes and proteins are core components of the mitotic DNA replication checkpoint signaling pathway (GO:0033314) and are frequently studied using CRISPR-based models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ATR | Sensor kinase that detects replication stress and initiates checkpoint signaling | Target for cancer therapy; knockout causes replication catastrophe |
| ATM | Kinase that responds to DNA double-strand breaks and overlaps with checkpoint signaling | Mutations cause ataxia-telangiectasia; target in DDR studies |
| CHEK1 | Effector kinase that amplifies checkpoint signal and inhibits CDC25 | Key therapeutic target; inhibitors in clinical trials |
| CHEK2 | Effector kinase involved in DNA damage response and checkpoint control | Mutations associated with cancer predisposition |
| WEE1 | Kinase that phosphorylates and inhibits CDK1 | Target for cancer therapy; inhibitor AZD1775 in trials |
| CDC25A | Phosphatase that activates CDK1; inhibited by checkpoint | Oncogene; overexpression drives premature mitosis |
| CDC25B | Phosphatase that activates CDK1; regulated by checkpoint | Involved in mitotic entry control |
| CDC25C | Phosphatase that dephosphorylates CDK1 to promote mitosis | Checkpoint target; loss causes mitotic defects |
| CDK1 | Cyclin-dependent kinase that drives mitotic entry | Central cell cycle regulator; target of checkpoint |
| CCNB1 | Cyclin B1, regulatory subunit of CDK1 | Essential for mitosis; overexpression causes mitotic defects |
| TOPBP1 | Scaffold protein that activates ATR at stalled forks | Required for checkpoint signaling; knockout is lethal |
| RPA1 | Single-stranded DNA-binding protein that recruits ATR | Essential for replication stress response |
| MCM2 | Component of the replicative helicase; marker of replication licensing | Used to assess replication origin firing |
| CDC45 | Component of the CMG helicase; required for replication fork progression | Target for replication stress studies |
| CLASPIN | Adaptor protein that facilitates CHEK1 activation by ATR | Required for checkpoint signaling; knockout sensitizes to replication stress |
| TIMELESS | Component of the replication fork protection complex | Involved in checkpoint activation and fork stability |
| TIPIN | Component of the replication fork protection complex | Required for ATR signaling at stalled forks |
How Is mitotic DNA replication checkpoint signaling Regulated?
The mitotic DNA replication checkpoint is regulated at multiple levels. The ATR-CHEK1 axis is controlled by recruitment of ATR to RPA-coated single-stranded DNA via ATRIP and TOPBP1. Phosphorylation of CHEK1 by ATR at Ser317 and Ser345 is required for its activation. The checkpoint is also modulated by phosphatases (e.g., PP2A, WIP1) that reverse phosphorylation events, allowing checkpoint recovery after replication completion. Additionally, the checkpoint is integrated with the circadian clock and developmental signals, though the exact mechanisms remain areas of active investigation.
mitotic DNA replication checkpoint signaling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ATR | Seckel syndrome, cancer predisposition | Knockout and point-mutation cell lines; mouse models |
| CHEK1 | Cancer, chemoresistance | Knockout and overexpression models; xenografts |
| WEE1 | Cancer, sensitivity to DNA-damaging agents | Knockout and point-mutation models; organoids |
| CDC25A | Cancer, premature mitosis | Overexpression and knockout models |
| ATM | Ataxia-telangiectasia, cancer | Knockout and knock-in models; patient-derived cells |
Cancer and genome instability
Dysregulation of the mitotic DNA replication checkpoint is a hallmark of cancer. Loss of checkpoint function allows cells to enter mitosis with damaged or incompletely replicated DNA, leading to genome instability, aneuploidy, and tumor progression. Conversely, cancer cells with defects in other DNA repair pathways may become dependent on the replication checkpoint for survival, creating therapeutic opportunities. Inhibitors of ATR, CHEK1, and WEE1 are currently in clinical trials for various cancers. Whole-genome doubling, a common event in tumors, confers unique genetic vulnerabilities that can be exploited by targeting checkpoint pathways.
Congenital microcephaly and neurodevelopmental disorders
Mutations in genes involved in the DNA replication checkpoint cause congenital microcephaly, a condition characterized by a severely reduced brain size. For example, mutations in ATR or other checkpoint components lead to Seckel syndrome and related microcephalic primordial dwarfism disorders. These conditions highlight the importance of the checkpoint for normal development, particularly in tissues with high proliferative demands such as the developing brain.
Environmental toxicology and chemical exposure
Exposure to environmental chemicals can interfere with the replication checkpoint. For instance, the agricultural chemical thiabendazole has been shown to affect cell cycle and DNA damage response pathways, including checkpoint signaling, as revealed by network toxicology and molecular docking studies. Understanding how such chemicals modulate the checkpoint is important for assessing human health risks.
From mitotic DNA replication checkpoint signaling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ATR abolish the replication checkpoint? | ATR knockout cell lines (e.g., HCT116, U2OS) |
| How do cancer-associated CHEK1 mutations affect checkpoint function? | CHEK1 point-mutation knock-in models |
| Can WEE1 inhibition sensitize tumors to chemotherapy? | WEE1 knockout and overexpression xenografts |
| What is the role of CDC25A in mitotic entry? | CDC25A overexpression and knockout models |
| How does whole-genome doubling affect checkpoint dependency? | Isogenic diploid vs. tetraploid cell lines |
| Can CRISPR screening identify synthetic lethal partners? | Genome-wide CRISPR knockout library screening |
How to Study the mitotic DNA replication checkpoint signaling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Gene function loss | Determine if gene is required for checkpoint |
| CRISPR point mutation | Specific amino acid function | Study phosphorylation sites or disease mutations |
| RNA-seq | Transcriptional changes | Identify downstream targets and pathways |
| Phosphoproteomics | Phosphorylation events | Map signaling network |
| Live-cell imaging | Real-time mitotic entry | Assess checkpoint dynamics |
| Flow cytometry | Cell cycle distribution | Detect premature mitosis |
| CRISPR library screening | Synthetic lethal interactions | Identify therapeutic targets |
CRISPR knockout and point-mutation models
CRISPR-Cas9 technology enables the generation of knockout cell lines for any checkpoint gene, allowing researchers to assess its requirement for checkpoint signaling. Point-mutation knock-in models can be used to study specific phosphorylation sites or disease-associated mutations, providing insights into gene function at the molecular level.
RNA sequencing and transcriptomics
RNA-seq can reveal global transcriptional changes upon checkpoint activation or inhibition, identifying downstream targets and compensatory pathways. This approach is particularly useful for understanding how cancer cells adapt to checkpoint loss.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can quantify changes in protein abundance and phosphorylation status following checkpoint activation. Phosphoproteomics is especially powerful for mapping the signaling network downstream of ATR and CHEK1.
Live-cell imaging and flow cytometry
Live-cell imaging with fluorescent reporters (e.g., CDK1 activity biosensors) allows real-time monitoring of mitotic entry dynamics. Flow cytometry can assess cell cycle profiles and DNA content, revealing checkpoint defects such as premature mitosis.
How CRISPR Can Be Used to Study GO:0033314 mitotic DNA replication checkpoint signaling
Knockout
CRISPR knockout of checkpoint genes such as ATR, CHEK1, or WEE1 results in loss of the replication checkpoint, leading to premature mitotic entry and mitotic catastrophe. These models are invaluable for studying the essentiality of each component and for identifying synthetic lethal interactions.
Point Mutation
Point-mutation knock-in models allow precise interrogation of phosphorylation sites (e.g., CHEK1 Ser317/Ser345) or disease-associated mutations. For example, knocking in a kinase-dead mutation can separate the checkpoint function of a gene from its other roles.
Knock-in
Knock-in of tagged versions of checkpoint proteins (e.g., GFP-ATR) enables live-cell imaging and proteomic analysis. This approach is useful for studying protein localization, interactions, and dynamics during checkpoint activation.
Overexpression
Overexpression of checkpoint genes or their dominant-negative mutants can dysregulate the checkpoint. For instance, overexpressing CDC25A can override the checkpoint and force premature mitosis, providing a tool to study checkpoint bypass.
How EDITGENE Supports mitotic DNA replication checkpoint signaling Research
Researchers studying mitotic DNA replication checkpoint signaling-related genes often need to determine whether a candidate gene is causally involved in checkpoint control, and to dissect its molecular mechanism using precise genetic models. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for mitotic DNA replication checkpoint signaling research.
Frequently Asked Questions About mitotic DNA replication checkpoint signaling
What is GO:0033314?
GO:0033314 is the Gene Ontology term for mitotic DNA replication checkpoint signaling, a biological process that delays mitotic entry when DNA replication is incomplete or stalled.
What genes are involved in the mitotic DNA replication checkpoint?
Key genes include ATR, ATM, CHEK1, CHEK2, WEE1, CDC25A/B/C, CDK1, CCNB1, TOPBP1, RPA1, MCM2, CDC45, CLASPIN, TIMELESS, and TIPIN.
How does the mitotic DNA replication checkpoint work?
It detects replication stress via ATR, amplifies the signal through CHEK1, and inhibits CDK1-Cyclin B by blocking CDC25 phosphatases and activating WEE1, thereby preventing mitosis.
Why is the mitotic DNA replication checkpoint important in cancer?
Loss of this checkpoint causes genome instability and aneuploidy, which drive cancer progression. Conversely, cancer cells with defects in other repair pathways may depend on this checkpoint for survival, making it a therapeutic target.
What diseases are associated with defects in mitotic DNA replication checkpoint signaling?
Defects are linked to cancer, congenital microcephaly (e.g., Seckel syndrome), and genome instability syndromes.
What is the S-M checkpoint?
The S-M checkpoint is a synonym for the mitotic DNA replication checkpoint, referring to the surveillance mechanism that ensures mitosis (M) does not begin until DNA synthesis (S) is complete.
How can I study the mitotic DNA replication checkpoint using CRISPR?
CRISPR knockout, point-mutation knock-in, and overexpression models can be used to dissect gene function. EDITGENE provides these services.
What are the therapeutic implications of targeting the mitotic DNA replication checkpoint?
Inhibitors of ATR, CHEK1, and WEE1 are in clinical trials as anticancer agents, especially for tumors with replication stress or DNA repair defects.
What is the role of ATR in the mitotic DNA replication checkpoint?
ATR is the primary sensor kinase that detects replication stress and initiates the checkpoint signaling cascade by activating CHEK1.
How does whole-genome doubling affect checkpoint dependency?
Whole-genome doubling creates unique genetic vulnerabilities, including increased dependence on checkpoint pathways, which can be exploited therapeutically.
Conclusion
The mitotic DNA replication checkpoint signaling pathway (GO:0033314) is a critical guardian of genome integrity, ensuring that cells do not divide until their DNA is fully replicated. Its dysregulation is central to cancer and developmental disorders, making it a prime target for therapeutic intervention. Advances in CRISPR-based models and screening technologies are accelerating our understanding of this pathway and enabling the discovery of new drugs. EDITGENE is committed to supporting this research with high-quality gene editing services.
References
- 1. Glaviano A et al.. 2025. Cell cycle dysregulation in cancer.. Pharmacol Rev 77(2):100030 PMID: 40148026
- 2. Alcantara D et al.. 2014. Congenital microcephaly.. Am J Med Genet C Semin Med Genet 166C(2):124-39 PMID: 24816482
- 3. Quinton RJ et al.. 2021. Whole-genome doubling confers unique genetic vulnerabilities on tumour cells.. Nature 590(7846):492-497 PMID: 33505027
- 4. Jiang M et al.. 2021. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.. Acta Pharm Sin B 11(10):2983-2994 PMID: 34729299
- 5. Boddy MN et al.. 1999. DNA replication checkpoint control.. Front Biosci 4:D841-8 PMID: 10577839
- 6. Canman CE. 2001. Replication checkpoint: preventing mitotic catastrophe.. Curr Biol 11(4):R121-4 PMID: 11250164
- 7. He J et al.. 2024. Network toxicological and molecular docking to investigate the mechanisms of toxicity of agricultural chemical Thiabendazole.. Chemosphere 363:142711 PMID: 38964723
- 8. Lemmens B et al.. 2019. DNA replication and mitotic entry: A brake model for cell cycle progression.. J Cell Biol 218(12):3892-3902 PMID: 31712253
